Our approach to office management of asthma exacerbations in adults and adolescents
Our approach to office management of asthma exacerbations in adults and adolescents
PEF: peak expiratory flow;
SpO2: pulse oxygen saturation;
SABA: short-acting beta-agonist;
MDI: metered dose inhaler;
GC: glucocorticoid;
LABA: long-acting beta-agonist.
* In a minority of patients, symptoms resolve quickly and completely with one dose of albuterol (eg, 2 to 4 inhalations or one nebulizer treatment) and PEF is ≥80% of predicted or personal best. Oral glucocorticoid is not necessary, but a step-up in controller medication may be needed.
¶ Refer to UpToDate content on asthma management or https://ginasthma.org/.
Δ Comorbid conditions that may complicate asthma exacerbation include the following:
Acute bronchitis
Acute bacterial sinusitis
Heart failure; arrhythmia
Influenza, COVID-19
Pneumonia
Pneumothorax
Suggestive symptoms include fever, myalgias, purulent sputum, chest pain, poor response to SABA. Refer to UpToDate content on diagnosis and management.
◊ Individuals with PEF 60-70% of predicted following initial treatment can sometimes safely continue treatment at home if their symptoms are improving, they have an asthma-safe home environment, have the necessary medications and understand their proper administration, are deemed adherent to therapy, and have ready access to emergent care if needed.
Reference: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available from: www.ginasthma.org. (Accessed on December 15, 2021)